✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Concord Drugs Ltd.

CONCORD

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹56 Cr.
P/E
166.67

Concord Drugs Ltd.

  • Concord Drugs
  • Bacil Pharma
  • Medicamen Organics
FAQs on Concord Drugs Ltd. Shareprice

Concord Drugs has given better returns compared to its competitors.
Concord Drugs has grown at ~45.53% over the last 1yrs while peers have grown at a median rate of -31.0%

Yes, Concord Drugs is expensive.
Latest PE of Concord Drugs is 166, while 3 year average PE is 25.47.
Also latest EV/EBITDA of Concord Drugs is 17.59 while 3yr average is 11.11.

View FAQ's On Business
Growth Table
  • Concord Drugs Ltd.
  • Bacil Pharma
  • Medicamen Organics
Balance Sheet
  • Concord Drugs Ltd.
  • Bacil Pharma
  • Medicamen Organics
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Concord Drugs Ltd.
  • Bacil Pharma
  • Medicamen Organics
Cash Flow
  • Concord Drugs Ltd.
  • Bacil Pharma
  • Medicamen Organics
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Concord Drugs Ltd.
  • Bacil Pharma
  • Medicamen Organics
Quarterly Results
  • Concord Drugs Ltd.
  • Bacil Pharma
  • Medicamen Organics
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Concord Drugs Ltd. Financials

Balance sheet of Concord Drugs is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Concord Drugs is decreasing.
Latest net debt of Concord Drugs is ₹16.97 Crs as of Mar-25.
This is less than Mar-24 when it was ₹17.31 Crs.

No, profit is decreasing.
The profit of Concord Drugs is ₹0.47 Crs for Mar 2024, ₹0.99 Crs for Mar 2023 and ₹1.59 Crs for Mar 2022

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech